Table 2.
The relation between GLUT-1 expression and clinicopathological parameters in 190 advanced gastric cancer cases.
Clinicopathological parameters | GLUT-1 expression | P-value | |
---|---|---|---|
Negative (score 0) n=74 |
Positive (score 1~2) n=116 |
||
Gender | 0.191 | ||
Male | 49 (66.2%) | 87 (75.0%) | |
Female | 25 (33.8%) | 29 (25.0%) | |
Age (year) | 63±14 | 66±11 | 0.099a |
Tumor diameter (cm) | 4.78±2.35 | 5.68±2.48 | 0.007a,* |
Tumor localization | 0.039* | ||
Upper | 9 (12.2%) | 32 (27.6%) | |
Middle | 14 (18.9%) | 16 (13.8%) | |
Lower | 51 (68.9%) | 68 (58.6%) | |
pT | 0.382b | ||
T2 | 14 (18.9%) | 14 (12.1%) | |
T3 | 1 (1.4%) | 3 (2.6%) | |
T4 (T4a, T4b) | 59 (79.7%) | 99 (85.3%) | |
pN | 0.328 | ||
N0 | 9 (12.2%) | 26 (22.4%) | |
N1 | 13 (17.5%) | 21 (18.1%) | |
N2 | 21 (28.4%) | 29 (25.0%) | |
N3 (N3a, N3b) | 31 (41.9%) | 40 (34.5%) | |
M | 0.012b,* | ||
M0 | 72 (97.3%) | 101 (87.1%) | |
M1 | 2 (2.7%) | 15 (12.9%) | |
TNM stage | 0.233b | ||
IB | 3 (4.0%) | 7 (6.0%) | |
IIA, IIB | 15 (20.3%) | 23 (19.8%) | |
IIIA, IIIB, IIIC | 54 (73.0%) | 75 (64.7%) | |
IV | 2 (2.7%) | 11 (9.5%) | |
Histology | <0.001b,* | ||
Well differentiated | 8 (10.8%) | 20 (17.3%) | <0.001b,c,* |
Moderately differentiated | 16 (21.6%) | 57 (49.1%) | |
Poorly differentiated | 43 (58.1%) | 34 (29.3%) | |
Signet-ring cell | 6 (8.1%) | 3 (2.6%) | |
Mucinous | 1 (1.4%) | 2 (1.7%) | |
Lauren type | <0.001* | ||
Intestinal | 24 (32.4%) | 77 (66.4%) | |
Diffuse | 50 (67.6%) | 39 (33.6%) | |
Venous invasion | 0.085 | ||
Positive | 55 (74.3%) | 98 (84.5%) | |
Negative | 19 (25.7%) | 18 (15.5%) | |
Lymphatic invasion | 0.100 | ||
Positive | 65 (87.8%) | 91 (78.4%) | |
Negative | 9 (12.2%) | 25 (21.6%) | |
Perineural invasion | 0.265 | ||
Positive | 50 (67.6%) | 87 (75.0%) | |
Negative | 24 (32.4%) | 29 (25.0%) |
Mann-Whitney U test;
Fisher’s exact test;
Comparison of different grade in adenocarcinoma.
P<0.05.
GLUT-1 – glucose transporter-1.